An alpha-MSH analog approved as an implant for a rare light-sensitivity disorder.
Key takeaway
Afamelanotide increases melanin production in the skin. It is FDA-approved as Scenesse, an implant that increases pain-free light exposure in adults with erythropoietic protoporphyria.
At a glance
| FDA status | In an FDA-approved drug |
|---|---|
| 503A compounding | Eligible for 503A compounding (component of an approved drug) |
| Body areas | Skin & hair |
| Through ScriptMates | Information only |
| Open questions | 1 noted below |
What is Melanotan I (afamelanotide)?
Afamelanotide increases melanin production in the skin. It is FDA-approved as Scenesse, an implant that increases pain-free light exposure in adults with erythropoietic protoporphyria.
Our 503A partner pharmacies do not list it, so it is shown for information only.
Dosage forms
FDA-approved Scenesse contains afamelanotide as an implant for subcutaneous use. This approval does not extend to other products sold as Melanotan I.
Is Melanotan I (afamelanotide) FDA-approved?
Active ingredient of FDA-approved Scenesse (afamelanotide implant).
Can it be prescribed through ScriptMates?
Eligible for 503A compounding (component of an approved drug). No ScriptMates 503A partner pharmacy lists this peptide, so it is shown for information only.
What we could not confirm
- Catalog items named “Melanotan I” are assumed to be afamelanotide.
Sources
Checked October 27, 2026. FDA updates these pages, so confirm before relying on them.